Global Non-ossifying Fibromas Market – Industry Trends and Forecast to 2030

Global Non-ossifying Fibromas Market, By Treatment (Curettage, Cryotherapy, Bone Grafting, Others), Diagnosis (X-ray, Biopsy, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.

Non-Ossifying Fibromas Market Analysis and Size

The increase in the incidence of non-ossifying fibroma and growing healthcare expenditure are the primary factors boosting the market growth rate. Non-ossifying fibromas are the most common benign bone tumors witnessed in children, affecting around 20-40%. No known cause, the genetic link, or risk factor is involved in the growth of a non-ossifying fibroma. Numerous manufacturers are assisting in developing numerous treatment processes to help the market grow.

Data Bridge Market Research analyses that the non-ossifying fibromas market, which was USD 3.25 billion in 2022, would rise up to USD 5 billion by 2030 and is expected to undergo a CAGR of 5.50% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Non-Ossifying Fibromas Market Scope and Segmentation

Market Definition

Non-ossifying fibromas (NOF) is a type of benign tumor, a collection of abnormal cells that do not spread to other body parts. These fibromas are more prevalent in men than in women, and they are often discovered after an x-ray of the area is taken for another reason, such as pain after a fall. Several children suffering from NOFs have no symptoms, and these benign tumors typically vanish without therapy.  

Global Non-Ossifying Fibromas Market Dynamics

Drivers

• Increasing R&D for Cancer Drugs and Treatment

The increasing incidence of this fibroma is expected to enhance market growth. It is predicted that NOF may be present in up to 30% of children. Non-ossifying fibromas are prevalent in children and adolescents and are considered the most common benign tumor. It has been witnessed that non-ossifying fibroma is one of the most common benign fibrous bone lesions, with an average prevalence of 30-40% globally in 2021, particularly in males, between the age group of 2 and 20 years. Thus, this factor leads to the growth of the market.

• Increasing Availability of Diagnostic Measures of NOF

There are varied diagnostic measures associated with NOF that lead to market growth. The diagnosis of non-ossifying fibromas is primarily based on characteristic radiographic or imaging features. X-rays are generally sufficient to detect a non-ossifying fibroma and to identify its growth from time to time. If the tumor is comparatively large, healthcare professionals may require a detailed imaging test, such as an MRI or CT scan, to look closely at the bone and check for signs of weakening. Thus, this factor help in the market growth.

Opportunities

• Increasing Demand for Treatment Processes

There is a huge growth of treatment processes that increases the market growth. Non-ossifying fibromas are removed through a surgical procedure known as curettage. If they are large, as in involving >50% of the diameter of the parent bone, then prophylactic curettage and bone grafting may be necessary to avoid a pathological fracture. A bone graft may be taken from a donor or another bone in the body. Thus, this factor boosts market growth.  

Restraints/Challenges

• High Cost of NOF Treatment

The treatment of NOF is much higher in cost, leading to market hindrance. The surgical treatment methods, including curettage and bone grafting, lead to very high costs, which many patients cannot afford in the economic section. Thus, the increasing cost of treatment and drugs is anticipated to impede market growth during the forecast period.  

This non-ossifying fibromas market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-ossifying fibromas market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Non-Ossifying Fibromas Market Scope

The non-ossifying fibromas market is segmented on the basis of  treatment, diagnosis, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Curettage
• Cryotherapy
• Bone Grafting
• Others

Diagnosis

• X-ray, Biopsy
• Computed Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI)
• Others

End-User

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Non-Ossifying Fibromas Market Regional Analysis/Insights

The non-ossifying fibromas market is analyzed and market size insights and trends are provided by  treatment, diagnosis, end-users and distribution channel as referenced above.

The countries covered in the non-ossifying fibromas market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to grow during the forecast period of the non-ossifying fibromas market because of the growing research and development activities and rising investment in the healthcare sector. Also, increasing government support for its treatment and diagnostic methods leads to the enhancement of the market.

North America dominates the market in the forecast period due to the wide presence of major market players and high disposable income. Also, well-developed healthcare infrastructure in this region leads to market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The non-ossifying fibromas market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for non-ossifying fibromas market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the non-ossifying fibromas market. The data is available for historic period 2011-2021.

Competitive Landscape and Global Non-Ossifying Fibromas Market Share Analysis

The non-ossifying fibromas market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to non-ossifying fibromas market.

Some of the major players operating in the non-ossifying fibromas market are:

• Quantum Cryogenics (U.K.)
• BTG International Inc. (U.S.)
• CryoConcepts LP (U.S.)
• Zimmer MedizinSysteme GmbH (Germany)
• Medtronic (Ireland)
• Cortex Technology (Denmark)
• CooperSurgical, Inc. (U.S.)
• AtriCure, Inc (U.S.)., Hologic, Inc. (U.S).
• PHYSIOMED AG (Germany)
• BOWA MEDICAL (Germany)
• Prima Medical (U.K.)
• XcelLance Medical Technologies Pvt. Ltd.(India)
• Smith+Nephew (U.K.)